bioAffinity Technologies Inc 2026年季度报告

FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended March 31, 2026 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ______ to ______. COMMISSION FILE NUMBER: 001-41463 bioAffinity Technologies, Inc.(Exact name of registrant as specified in its charter) Delaware46-5211056(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.) 3300 Nacogdoches Road, Suite 216, San Antonio, Texas78217(Address of principal executive offices)(Zip Code) (210) 698-5334(Registrant’s telephone number, including area code) Not Applicable(Former name, former address and former fiscal year, if changed since last report) Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $0.007 per shareTradeable Warrants to purchase Common Stock The Nasdaq Stock Market LLCThe Nasdaq Stock Market LLC Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),and (2) has been subject to the filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒Emerging growth company☒ Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Sec 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ The number of shares of the issuer’s common stock outstanding as of May 4, 2026, was 4,534,906. Throughout this Quarterly Report on Form 10-Q (this “Quarterly Report”), the terms “bioAffinity,” “bioAffinity Technologies,” “we,”“us,” “our” or “the Company” refer to bioAffinity Technologies, Inc., a Delaware corporation, and its wholly owned subsidiaries,OncoSelect®Therapeutics, LLC, a Delaware limited liability company, and Precision Pathology Laboratory Services, LLC, a Texaslimited liability company. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report contains forward-looking statements within the meaning of the federal securities laws. Forward-lookingstatements are predictive in nature, depend on or refer to future events or conditions, and are sometimes identified by words such as“may,” “could,” “plan,” “project,” “predict,” “pursue,” “believe,” “expect,” “estimate,” “anticipate,” “intend,” “target,” “seek,”“potentially,” “will likely result,” “outlook,” “budget,” “objective,” “trend,” or similar expressions of a forward-looking nature and thenegative versions of such expressions. The forward-looking information contained in this report is generally located under the heading“Management’s Discussion and Analysis of Financial Condition and Results of Operations” but may be found in other locations aswell. The forward-looking statements in this report generally relate to the plans and objectives for future operations of bioAffinityTechnologies, Inc. and are based on our management’s reasonable estimates of future results or trends. Although we believe theseforward-looking statements are reasonable, all forward-looking statements are subject to various risks and uncertainties, and ourprojections and expectations may be incorrect. The factors that may affect our expectations regarding our operations include, amongothers, the following: ●our projected financial position and estimated cash burn rate;●our estimates regarding expenses, future revenues, and capital requirements;●the success, cost, and timing of our clinical trials;●our ability to obtain funding for our operations necessary to complete further development and commercialization of ourdiagnostic tests or therapeutic product candidates;●our dependence on third parties in the conduct of our clinical trials;●our ability to obtain the necessary regulatory approvals to market and commercialize our diagnostic tests or therapeuticproduct candidates;●the potential